YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

Phibro Animal Health's PAHC diversified product portfolio and wide presence in key growth areas bolster our confidence in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021.

In a report released today, Glen Santangelo from Jefferies maintained a Buy rating on Elanco Animal Health (ELAN – Research Report), with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Ascendis Pharma grants Novo Nordisk exclusive global license for TransCon tech in metabolic and cardiovascular disease products. Ascendis eligible for $285 million upfront, milestone, and sales ...

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the ...

Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery technology to advance a long-acting GLP-1 drug as well as develop products in ...

Phibro Animal Health (NASDAQ:PAHC) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Phibro ...

Ascendis Health Ltd is listed and trades on the Johannesburg stock exchange. What Is the Stock Symbol for Ascendis Health Ltd? The stock symbol for Ascendis Health Ltd is "ASCJ." What Is the Ascendis ...